Summary of Study ST004138

This data is available at the NIH Common Fund's National Metabolomics Data Repository (NMDR) website, the Metabolomics Workbench, https://www.metabolomicsworkbench.org, where it has been assigned Project ID PR002603. The data can be accessed directly via it's Project DOI: 10.21228/M85Z50 This work is supported by NIH grant, U2C- DK119886.

See: https://www.metabolomicsworkbench.org/about/howtocite.php

This study contains a large results data set and is not available in the mwTab file. It is only available for download via FTP as data file(s) here.

Perform statistical analysis  |  Show all samples  |  Show named metabolites  |  Download named metabolite data  
Download mwTab file (text)   |  Download mwTab file(JSON)   |  Download data files (Contains raw data)
Study IDST004138
Study TitleVariation in microbiome and metabolites are associated with advantageous effects of cholestyramine on primary biliary cholangitis with pruritus
Study SummaryThis study aimed to elucidate the gut microbiota-metabolite interplay in cholestatic pruritus associated with primary biliary cholangitis (PBC) and the therapeutic mechanisms of cholestyramine. A prospective cohort of 54 pruritic PBC patients and 25 asymptomatic controls underwent longitudinal multi-omics profiling. Participants received 4 g cholestyramine twice daily for 4 weeks, with paired fecal 16S rRNA sequencing, untargeted LC/MS metabolomics, and serum analyses (autotaxin [ATX], liver function) pre-/post-intervention. Key findings revealed: 1.Pruritic patients exhibited elevated cholestasis markers (bilirubin, ALP, GGT; P<0.01), ATX levels, and Gp210 antibody positivity. Cholestyramine significantly reduced 5-D itch scores, ATX, and cholestasis indices (P<0.01). 2.Gut microbial diversity (Shannon/Simpson) was depleted in pruritus, with enrichment of Romboutsia, Stenotrophomonas, and Achromobacter versus Lachnospiraceae/Bacteroidaceae in controls. 3.LC/MS metabolomics identified critical perturbations: ↓ Medium-chain fatty acids (MCFAs: C8-C14) ↓ Indole derivatives (e.g., norharman) 4.Microbial-metabolite-clinical correlations implicated the Romboutsia–norharman–ATX/ALP axis in pruritogenesis. Cholestyramine restored microbial diversity, normalized metabolites, and attenuated pruritus. Enterobacteriaceae/long-chain fatty acids predicted treatment response.
Institute
Hangzhou Xixi Hospital
Last NameZhou
First NameYijun
AddressNo.2, Hengbu Street, Xihu District, Hangzhou, Zhejiang Province, China, Hangzhou, Zhejiang, 310023, China
Email348611334@qq.com
Phone+8613588296223
Submit Date2025-07-27
Raw Data AvailableYes
Raw Data File Type(s)raw(Thermo)
Analysis Type DetailLC-MS
Release Date2025-11-24
Release Version1
Yijun Zhou Yijun Zhou
https://dx.doi.org/10.21228/M85Z50
ftp://www.metabolomicsworkbench.org/Studies/ application/zip

Select appropriate tab below to view additional metadata details:

Project:

Project ID:PR002603
Project DOI:doi: 10.21228/M85Z50
Project Title:Variation in microbiome and metabolites are associated with advantageous effects of cholestyramine on primary biliary cholangitis with pruritus
Project Summary:Pruritus in PBC arises from synergistic cholestasis and gut microbiome-metabolite dysregulation. Cholestyramine mitigates symptoms by modulating the microbiome - metabolite - host axis, highlighting its therapeutic potential through microbiota remodeling and metabolic homeostasis restoration.
Institute:Hangzhou Xixi Hospital
Last Name:Zhou
First Name:Yijun
Address:No.2, Hengbu Street, Xihu District, Hangzhou, Zhejiang Province, China, Hangzhou, Zhejiang, 310023, China
Email:348611334@qq.com
Phone:+8613588296223

Subject:

Subject ID:SU004288
Subject Type:Human
Subject Species:Homo sapiens
Taxonomy ID:9606

Factors:

Subject type: Human; Subject species: Homo sapiens (Factor headings shown in green)

mb_sample_id local_sample_id Sample source Treatment
SA476979C6human_stool post-4-week cholestyramine
SA476980C27human_stool post-4-week cholestyramine
SA476981C28human_stool post-4-week cholestyramine
SA476982C3human_stool post-4-week cholestyramine
SA476983C32human_stool post-4-week cholestyramine
SA476984C33human_stool post-4-week cholestyramine
SA476985C34human_stool post-4-week cholestyramine
SA476986C35human_stool post-4-week cholestyramine
SA476987C36human_stool post-4-week cholestyramine
SA476988C37human_stool post-4-week cholestyramine
SA476989C38human_stool post-4-week cholestyramine
SA476990C39human_stool post-4-week cholestyramine
SA476991C4human_stool post-4-week cholestyramine
SA476992C40human_stool post-4-week cholestyramine
SA476993C5human_stool post-4-week cholestyramine
SA476994C9human_stool post-4-week cholestyramine
SA476995C24human_stool post-4-week cholestyramine
SA476996P54human_stool post-4-week cholestyramine
SA476997P55human_stool post-4-week cholestyramine
SA476998P56human_stool post-4-week cholestyramine
SA476999P59human_stool post-4-week cholestyramine
SA477000P60human_stool post-4-week cholestyramine
SA477001P61human_stool post-4-week cholestyramine
SA477002P63human_stool post-4-week cholestyramine
SA477003P64human_stool post-4-week cholestyramine
SA477004P65human_stool post-4-week cholestyramine
SA477005P66human_stool post-4-week cholestyramine
SA477006P67human_stool post-4-week cholestyramine
SA477007P69human_stool post-4-week cholestyramine
SA477008P70human_stool post-4-week cholestyramine
SA477009P71human_stool post-4-week cholestyramine
SA477010C25human_stool post-4-week cholestyramine
SA477011P62human_stool post-4-week cholestyramine
SA477012C23human_stool post-4-week cholestyramine
SA477013C17human_stool post-4-week cholestyramine
SA477014C22human_stool post-4-week cholestyramine
SA477015C10human_stool post-4-week cholestyramine
SA477016C13human_stool post-4-week cholestyramine
SA477017C15human_stool post-4-week cholestyramine
SA477018C14human_stool post-4-week cholestyramine
SA477019C18human_stool post-4-week cholestyramine
SA477020C19human_stool post-4-week cholestyramine
SA477021C2human_stool post-4-week cholestyramine
SA477022C20human_stool post-4-week cholestyramine
SA477023C21human_stool post-4-week cholestyramine
SA477024P26human_stool pre-4-week cholestyramine
SA477025P33human_stool pre-4-week cholestyramine
SA477026P31human_stool pre-4-week cholestyramine
SA477027P30human_stool pre-4-week cholestyramine
SA477028P29human_stool pre-4-week cholestyramine
SA477029P28human_stool pre-4-week cholestyramine
SA477030P27human_stool pre-4-week cholestyramine
SA477031P21human_stool pre-4-week cholestyramine
SA477032P25human_stool pre-4-week cholestyramine
SA477033P24human_stool pre-4-week cholestyramine
SA477034P23human_stool pre-4-week cholestyramine
SA477035P22human_stool pre-4-week cholestyramine
SA477036P35human_stool pre-4-week cholestyramine
SA477037P20human_stool pre-4-week cholestyramine
SA477038P19human_stool pre-4-week cholestyramine
SA477039P34human_stool pre-4-week cholestyramine
SA477040P43human_stool pre-4-week cholestyramine
SA477041P37human_stool pre-4-week cholestyramine
SA477042P48human_stool pre-4-week cholestyramine
SA477043P73human_stool pre-4-week cholestyramine
SA477044P53human_stool pre-4-week cholestyramine
SA477045P52human_stool pre-4-week cholestyramine
SA477046P51human_stool pre-4-week cholestyramine
SA477047P50human_stool pre-4-week cholestyramine
SA477048P49human_stool pre-4-week cholestyramine
SA477049P47human_stool pre-4-week cholestyramine
SA477050P38human_stool pre-4-week cholestyramine
SA477051P46human_stool pre-4-week cholestyramine
SA477052P45human_stool pre-4-week cholestyramine
SA477053P44human_stool pre-4-week cholestyramine
SA477054P17human_stool pre-4-week cholestyramine
SA477055P42human_stool pre-4-week cholestyramine
SA477056P41human_stool pre-4-week cholestyramine
SA477057P40human_stool pre-4-week cholestyramine
SA477058P18human_stool pre-4-week cholestyramine
SA477059P10human_stool pre-4-week cholestyramine
SA477060P16human_stool pre-4-week cholestyramine
SA477061P5human_stool pre-4-week cholestyramine
SA477062P15human_stool pre-4-week cholestyramine
SA477063P1human_stool pre-4-week cholestyramine
SA477064P3human_stool pre-4-week cholestyramine
SA477065P4human_stool pre-4-week cholestyramine
SA477066P2human_stool pre-4-week cholestyramine
SA477067P6human_stool pre-4-week cholestyramine
SA477068P8human_stool pre-4-week cholestyramine
SA477069P9human_stool pre-4-week cholestyramine
SA477070P11human_stool pre-4-week cholestyramine
SA477071P13human_stool pre-4-week cholestyramine
SA477072P14human_stool pre-4-week cholestyramine
SA477073A15human_stool ursodeoxycholic acid
SA477074A24human_stool ursodeoxycholic acid
SA477075A23human_stool ursodeoxycholic acid
SA477076A22human_stool ursodeoxycholic acid
SA477077A21human_stool ursodeoxycholic acid
SA477078A20human_stool ursodeoxycholic acid
Showing page 1 of 2     Results:    1  2  Next     Showing results 1 to 100 of 117

Collection:

Collection ID:CO004281
Collection Summary:Patients were required to fast overnight before collection of stool samples on the morning of each visit. Stool samples were centrifuged at 2800 rpm for 15 minutes at 4℃ and serum were aliquoted and stored at -80℃ until analysis. Fecal samples were freshly collected and immediately frozen at -80℃.
Sample Type:stool

Treatment:

Treatment ID:TR004297
Treatment Summary:A total of 54 pruritic PBC patients with 25 matched non-pruritic PBC patients were enrolled in this study. Cholestyramine was administered twice daily (4 g/dose) before meals, with a mandatory 4-hour separation from other medications to prevent UDCA absorption interference. Biochemical parameters, serum, and stool samples were collected at baseline and 4-week follow-up.

Sample Preparation:

Sampleprep ID:SP004294
Sampleprep Summary:Faecal metabolome profiling and data preprocessing Metabolites were extracted using a methanol-water (80:20, v/v) solution.

Chromatography:

Chromatography ID:CH005215
Chromatography Summary:Metabolite profiling was performed using liquid chromatography-mass spectrometry (LC-MS). The extracted metabolites were separated on a C18 reversed-phase column using a gradient elution with mobile phases consisting of water (0.1% formic acid) and acetonitrile (0.1% formic acid).
Instrument Name:Agilent 1260
Column Name:Thermo Hypersil GOLD aQ (100 x 2.1mm,1.9um)
Column Temperature:40°C
Flow Gradient:0.2 mL/min
Flow Rate:0.2 mL/min
Solvent A:100% water; 0.1% formic acid
Solvent B:100% Methanol
Chromatography Type:Reversed phase

Analysis:

Analysis ID:AN006860
Analysis Type:MS
Chromatography ID:CH005215
Num Factors:3
Num Metabolites:1037
Units:Peak area
  
Analysis ID:AN006861
Analysis Type:MS
Chromatography ID:CH005215
Num Factors:3
Num Metabolites:691
Units:Peak area
  logo